Cargando…
MAGEA1 and hTERT Peptide Treatment Improves the Potency of The Dendritic Cell- Cytotoxic T Lymphocytes (DC-CTL) Immunotherapy in DAC Treated Acute Myeloid Leukemia
Background: Acute myeloid leukemia (AML) is a type of heterogenous malignant hematological disorder. Recently developed immunotherapies such as chimeric antigen receptor T cell (CAR-T) do not demonstrated promising therapeutic results due to the off-target effect. The Dendritic cell-cytotoxic T lymp...
Autores principales: | Zhong, Guocheng, Zhao, Weiqiang, Li, Yisheng, Jin, Guangyi, Zeng, Wei, Yu, Changhua, Zhou, Ji, Yu, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899371/ https://www.ncbi.nlm.nih.gov/pubmed/35281868 http://dx.doi.org/10.7150/jca.66501 |
Ejemplares similares
-
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
por: Suso, Else M. Inderberg, et al.
Publicado: (2011) -
A Novel Long Non-Coding RNA in the hTERT Promoter Region Regulates hTERT Expression
por: Malhotra, Sanandan, et al.
Publicado: (2017) -
Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia
por: Zhong, Guocheng, et al.
Publicado: (2020) -
An Improved Model for the hTERT Promoter Quadruplex
por: Chaires, Jonathan B., et al.
Publicado: (2014) -
Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma
por: Õunap, Kadri, et al.
Publicado: (2018)